Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemostatic Effects of Velcade in Multiple Myeloma
NCT01720043Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Jul 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University of Utah. Primary endpoint: Platelet Aggregation at 48 hours. Started Jul 2013; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01720043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720043.